Acalabrutinib

Form: Oral Capsules

Strength: 100 mg

Reference Brands: Calquence® (EU & US)

Category: Oncology Cancer Care

Acalabrutinib Capsules are a Bruton’s tyrosine kinase (BTK) inhibitor used in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). By targeting and inhibiting BTK, Acalabrutinib prevents the survival and proliferation of malignant B-cells. Marketed under the brand name Calquence®, Acalabrutinib offers an effective solution for patients who have not responded to other treatments or as a first-line therapy. Available in a 100 mg oral capsule strength, Acalabrutinib is manufactured under GMP-compliant conditions, providing a reliable oncology treatment for US and EU markets.